Thu, Oct 2, 2014, 1:23 PM EDT - U.S. Markets close in 2 hrs 37 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • kvnmccdd kvnmccdd Feb 8, 2013 1:02 AM Flag

    Mergers and Acquisitions Within the Biotech Industry Expected to Rise in 2013

    NEW YORK, NY--(Marketwire - Jan 14, 2013) - Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology and pharmaceutical companies have occurred in the past three years

    At the end of the third quarter five of the biggest drug makers in the U.S. held over $70 billion in cash, near cash and short-term investments. Major revenue losses from patent expirations have forced big pharmaceutical companies to look to biotech companies to help fill the void. Pfizer's Lipitor and Bristol-Myers' Plavix, which lost exclusivity in late 2011, had combined annuals revenues of $17 billion at their peaks.

    "We're through many cost-cutting programs, restructurings and portfolio arrangements," said Henry Gosebruch, Managing Director, Mergers & Acquisitions J.P. Morgan. "When you put that together with record levels of cash available and improving, but still moderate R&D productivity, we think there will be more big pharma M&A activity in 2013."

    Sentiment: Strong Buy

 
INSM
13.03+0.46(+3.66%)1:23 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.